Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Overall survival: Median length of · people with metastatic breast cancer

Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Disease-free survival · patients with early breast cancer

Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

DFS: hormone receptor‐positivemedian · patients with early breast cancer

Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

DFS: hormone receptor‐negativemedian · patients with early breast cancer

Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

OS: hormone receptor‐positivemedian · people with metastatic breast cancer

Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (high certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Overall survival: Median length of · patients with early breast cancer

Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Febrile neutropenia · patients with early breast cancer

Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Diarrhoea · patients with early breast cancer

Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Hand‐foot syndrome · patients with early breast cancer

Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

OS: hormone receptor‐negativemedian · people with metastatic breast cancer

Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (high certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Progression‐free survival · people with metastatic breast cancer

Capecitabine‐containing regimens probably leads to lower progression‐free survival (PFS)median compared with chemotherapy regimens without capecitabine (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

PFS: hormone receptor‐positivemedian · people with metastatic breast cancer

Capecitabine‐containing regimens probably leads to lower PFS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

PFS: hormone receptor‐negativemedian · people with metastatic breast cancer

Capecitabine‐containing regimens showed no clear difference in PFS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Objective response rate · people with metastatic breast cancer

Capecitabine‐containing regimens showed no clear difference in objective response rate compared with chemotherapy regimens without capecitabine (moderate certainty).

1 finding from 1 review